These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37592047)

  • 61. Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia.
    Baugh CW; Faridi MK; Mueller EL; Camargo CA; Pallin DJ
    PLoS One; 2019; 14(5):e0216835. PubMed ID: 31120893
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.
    Rosa RG; Goldani LZ
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3799-803. PubMed ID: 24752269
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia.
    Chindaprasirt J; Wanitpongpun C; Limpawattana P; Thepsuthammarat K; Sripakdee W; Sookprasert A; Wirasorn K
    Asian Pac J Cancer Prev; 2013; 14(2):1115-9. PubMed ID: 23621197
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Home-based care of low-risk febrile neutropenia in children-an implementation study in a tertiary paediatric hospital.
    Haeusler GM; Gaynor L; Teh B; Babl FE; Orme LM; Segal A; Mechinaud F; Bryant PA; Phillips B; Lourenco RA; Slavin MA; Thursky KA
    Support Care Cancer; 2021 Mar; 29(3):1609-1617. PubMed ID: 32740894
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Efficacy of Levofloxacin Hydrate in Febrile Neutropenia for Outpatient Chemotherapy].
    Inagaki M; Sato J; Nihei S; Kashiwaba M; Kudo K
    Gan To Kagaku Ryoho; 2016 May; 43(5):593-6. PubMed ID: 27210089
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
    Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
    Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy.
    Hwang S; Kwon KT; Kim Y; Bae S; Chang HH; Kim SW; Yoo SS; Nam SY; Baek JH
    Sci Rep; 2021 Sep; 11(1):9048. PubMed ID: 34526516
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
    Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
    J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early Discontinuation versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients with Febrile Neutropenia, Before Recovery of Counts: A Randomized Controlled Trial (DALFEN Study).
    Kumar A; Biswas B; Chopra A; Kapil A; Vishnubhatla S; Bakhshi S
    Indian J Pediatr; 2021 Mar; 88(3):240-245. PubMed ID: 32537711
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia.
    Lal A; Bhurgri Y; Rizvi N; Virwani M; Memon RU; Saeed W; Sardar MR; Kumar P; Shaikh AJ; Adil S; Masood N; Khurshed M
    Asian Pac J Cancer Prev; 2008; 9(2):303-8. PubMed ID: 18712980
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department.
    Keng MK; Thallner EA; Elson P; Ajon C; Sekeres J; Wenzell CM; Seastone DJ; Gallagher EM; Weber CM; Earl MA; Mukherjee S; Pohlman B; Cober E; Foster VB; Yuhas J; Kalaycio ME; Bolwell BJ; Sekeres MA
    J Oncol Pract; 2015 Nov; 11(6):450-5. PubMed ID: 26220930
    [TBL] [Abstract][Full Text] [Related]  

  • 73. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.
    Chao C; Page JH; Yang SJ; Rodriguez R; Huynh J; Chia VM
    Ann Oncol; 2014 Sep; 25(9):1821-1829. PubMed ID: 24915871
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predicting bacterial infections among pediatric cancer patients with febrile neutropenia: External validation of the PICNICC model.
    Ojha RP; Asdahl PH; Steyerberg EW; Schroeder H
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286572
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
    Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
    J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Managing low-risk febrile neutropenia in children in the time of COVID-19: What matters to parents and clinicians.
    Haeusler GM; De Abreu Lourenco R; Bakos C; O'Brien T; Slavin MA; Clark JE; McMullan B; Borland ML; Babl FE; Krishnasamy M; Vanevski M; Thursky KA; Hall L
    J Paediatr Child Health; 2021 Jun; 57(6):826-834. PubMed ID: 33533525
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Etiology and clinical course of febrile neutropenia in children with cancer.
    Hakim H; Flynn PM; Knapp KM; Srivastava DK; Gaur AH
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):623-9. PubMed ID: 19644403
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
    Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial.
    Miyake O; Murata K; Tanaka S; Ishiguro H; Toi M; Tamura K; Kawakami K
    Jpn J Clin Oncol; 2018 May; 48(5):410-416. PubMed ID: 29590407
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
    Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.